Due to the high rate of EGFR T790M mutations seen in NSCLC patients, the thoracic tumor board recommends genomic testing for this alteration; read our case of a 69-year-old woman with metastatic disease.
Emily Wynja, MSIV
Advertisement
Articles by Emily Wynja, MSIV
Advertisement
Latest Updated Articles
A Patient With EGFR-Mutated Lung Cancer Progressing on Erlotinib: Evaluating for a T790M Mutation With Limited TissuePublished: October 17th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
Atezolizumab/Vaccine Combo May Show Long-Term Survival in ES-SCLC
2
The Latest and Hottest Topics in ADCs: A Discussion With a Chemical Engineer
3
Post-IO Curative Treatment Conversion May Prolong Survival in Liver Cancer
4
PEF Ablation Yields Local Control, May Elicit Immune Response in Solid Tumors
5
